Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00475202
Status:
UNKNOWN
Last Update Posted:
2007-05-21
First Post:
2007-05-16
Brief Title:
Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers
Sponsor:
Assaf-Harofeh Medical Center
Organization:
Assaf-Harofeh Medical Center
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2007-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Diabetic foot ulcers are a major cause of morbidity and mortality accounting for approximately two-thirds of all non-traumatic amputations performed in the United States The cost of foot ulcers in diabetic patients averages almost 28000 for the two years after diagnosis of the ulcer Hyperbaric oxygen HBO serves as primary or adjunctive therapy for a diverse range of medical conditions HBO also has been used as an adjunct to antibiotics debridement and revascularization in the therapy of chronic nonhealing wounds associated with diabetes or non-diabetic vascular insufficiency
The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients with foot ulcers
The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients with foot ulcers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None